Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy
- 1 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Drug Investigation
- Vol. 31 (7), 507-517
- https://doi.org/10.2165/11590230-000000000-00000
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapyClinicoEconomics and Outcomes Research, 2011
- New treatment approaches in renal cell carcinomaAnti-Cancer Drugs, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Gastrosplenic Fistula From Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectivenessBritish Journal of Cancer, 2009
- Tolerability of first-line therapy for metastatic renal cell carcinomaCancer Treatment Reviews, 2009
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinomaAnnals of Oncology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007